Previous 10 | Next 10 |
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for can...
Today, we want to share our analysis of Bellicum Pharmaceuticals ( BLCM ) with you. Over the last year, its stock largely fluctuated, falling from ~ $7 in September 2018 to $0.78 in August 2019. Recently, the company’s stock price grew by more than 20% after Baker Bros. disclosed its ...
The following slide deck was published by Bellicum Pharmaceuticals, Inc. in conjunction with this Read more ...
NOTE - Please note this stock is trading near $1 and has a market cap of less than $100mn. Avisol Capital recommends strong due diligence and considerable second thoughts while planning to invest in such companies. Bellicum Pharmaceuticals ( BLCM ) is one strange company - it continues t...
It was another rocky week for the NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ), which opened at 3,243.06 points on Monday (August 26) and reached a high of 3,269.62 points on Tuesday (August 27). By Friday (August 30), the index had settled at 3,230.77 points as of 12:52 p.m. ED...
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare...
Bellicum Pharmaceuticals (NASDAQ: BLCM ) is up 6.6% after hours following an SEC filing disclosing Baker Bros. taking a 5.8% stake. More news on: Bellicum Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offerin...
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent Private Placement of up to $70.0 Million of Preferred Stock and Warrants and $12.1 Mil...
Bellicum Pharmaceuticals (NASDAQ: BLCM ) has priced its public offering of 575K shares of Series 1 preferred stock and seven-year warrants to purchase up to 57.5M common shares (100 shares/warrant) at $1 per share and accompanying warrant. Gross proceeds should be ~$57.5M (not sure of its ...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...